{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T12:23:01Z","timestamp":1791894181616,"version":"4.3.4"},"reference-count":139,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T00:00:00Z","timestamp":1779235200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T00:00:00Z","timestamp":1784073600000},"content-version":"vor","delay-in-days":56,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100013003","name":"Universit\u00e0 degli Studi di Cagliari","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100013003","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Gaucher disease (GD) exemplifies how a single genetic mutation can give rise to a complex multisystem disorder with profound hematological implications. Central to its pathophysiology is the lysosomal accumulation of glucosylceramide due to deficient glucocerebrosidase activity, together with abnormal folding and trafficking of the enzyme that induce endoplasmic reticulum stress and cellular dysfunction. These processes disrupt reticuloendothelial homeostasis and interfere with hematopoiesis. As a consequence, macrophage activation and chronic inflammation contribute to the cytopenias, splenomegaly, and hyperferritinemia that frequently lead patients to hematological evaluation. Despite significant therapeutic advances, GD remains under-recognized in routine hematology practice, often resulting in diagnostic delays and suboptimal management. The introduction of enzyme replacement therapy (ERT) and substrate reduction therapy (SRT) has transformed the treatment landscape by targeting the underlying metabolic defect and mitigating systemic inflammation. Early diagnosis and timely initiation of therapy are essential to prevent irreversible organ damage and improve long-term outcomes. This review provides an integrated hematological perspective on GD, highlighting its pathophysiological basis, clinical manifestations, and diagnostic challenges through a representative real-world clinical case. By linking biological mechanisms to practical diagnostic reasoning, the review aims to facilitate earlier recognition of GD in hematology practice and ultimately improve patient outcomes.<\/jats:p>","DOI":"10.1007\/s00277-026-06977-3","type":"journal-article","created":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T13:06:28Z","timestamp":1779282388000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Gaucher disease: the hematologist\u2019s perspective of a multisystemic disorder"],"prefix":"10.1007","volume":"105","author":[{"given":"Alessandro","family":"Costa","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olga","family":"Mulas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanni","family":"Caocci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,20]]},"reference":[{"key":"6977_CR1","volume-title":"De l\u2019epith\u00e9lioma primitif de la rate: Hypertrophie idiopathique de la rate sans leuc\u00e9mie","author":"E Gaucher","year":"1882","unstructured":"Gaucher E (1882) De l\u2019epith\u00e9lioma primitif de la rate: Hypertrophie idiopathique de la rate sans leuc\u00e9mie. Biblioth\u00e8que interuniversitaire de sant\u00e9, Paris"},{"key":"6977_CR2","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1586\/17474086.2016.1112732","volume":"9","author":"S Linari","year":"2016","unstructured":"Linari S, Castaman G (2016) Hematological manifestations and complications of Gaucher disease. Expert Rev Hematol 9:51\u201358. https:\/\/doi.org\/10.1586\/17474086.2016.1112732","journal-title":"Expert Rev Hematol"},{"key":"6977_CR3","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1097\/MPH.0000000000002506","volume":"45","author":"M Wang","year":"2023","unstructured":"Wang M, Li F, Zhang J, Lu C, Kong W (2023) Global Epidemiology of Gaucher Disease: an Updated Systematic Review and Meta-analysis. J Pediatr Hematol Oncol 45:181. https:\/\/doi.org\/10.1097\/MPH.0000000000002506","journal-title":"J Pediatr Hematol Oncol"},{"key":"6977_CR4","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1186\/s13023-021-02034-6","volume":"16","author":"S D\u2019Amore","year":"2021","unstructured":"D\u2019Amore S, Page K, Donald A, Taiyari K, Tom B, Deegan P, Tan CY, Poole K, Jones SA, Mehta A, Hughes D, Sharma R, Lachmann RH, Chakrapani A, Geberhiwot T, Santra S, Banka S, Cox TM, MRC GAUCHERITE Consortium (2021) In-depth phenotyping for clinical stratification of Gaucher disease. Orphanet J Rare Dis 16:431. https:\/\/doi.org\/10.1186\/s13023-021-02034-6","journal-title":"Orphanet J Rare Dis"},{"key":"6977_CR5","doi-asserted-by":"publisher","first-page":"1263","DOI":"10.1016\/S0140-6736(08)61522-6","volume":"372","author":"GA Grabowski","year":"2008","unstructured":"Grabowski GA (2008) Phenotype, diagnosis, and treatment of Gaucher\u2019s disease. Lancet 372:1263\u20131271. https:\/\/doi.org\/10.1016\/S0140-6736(08)61522-6","journal-title":"Lancet"},{"key":"6977_CR6","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1186\/s13023-020-01544-z","volume":"15","author":"T Dinur","year":"2020","unstructured":"Dinur T, Istaiti M, Frydman D, Becker-Cohen M, Szer J, Zimran A, Revel-Vilk S (2020) Patient reported outcome measures in a large cohort of patients with type 1 Gaucher disease. Orphanet J Rare Dis 15:284. https:\/\/doi.org\/10.1186\/s13023-020-01544-z","journal-title":"Orphanet J Rare Dis"},{"key":"6977_CR7","doi-asserted-by":"publisher","first-page":"2002","DOI":"10.1002\/ajmg.a.33527","volume":"152A","author":"W Packman","year":"2010","unstructured":"Packman W, Crosbie TW, Behnken M, Eudy K, Packman S (2010) Living with Gaucher disease: Emotional health, psychosocial needs and concerns of individuals with Gaucher disease. Am J Med Genet A 152A:2002\u20132010. https:\/\/doi.org\/10.1002\/ajmg.a.33527","journal-title":"Am J Med Genet A"},{"key":"6977_CR8","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1186\/s40035-024-00437-6","volume":"13","author":"X Zhang","year":"2024","unstructured":"Zhang X, Wu H, Tang B, Guo J (2024) Clinical, mechanistic, biomarker, and therapeutic advances in GBA1-associated Parkinson\u2019s disease. Transl Neurodegener 13:48. https:\/\/doi.org\/10.1186\/s40035-024-00437-6","journal-title":"Transl Neurodegener"},{"key":"6977_CR9","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1016\/j.conb.2021.11.004","volume":"72","author":"I Milenkovic","year":"2022","unstructured":"Milenkovic I, Blumenreich S, Futerman AH (2022) GBA mutations, glucosylceramide and Parkinson\u2019s disease. Curr Opin Neurobiol 72:148\u2013154. https:\/\/doi.org\/10.1016\/j.conb.2021.11.004","journal-title":"Curr Opin Neurobiol"},{"key":"6977_CR10","unstructured":"Hughes DA, Pastores GM (2023) Gaucher disease. In: Adam MP, Bick S, Mirzaa GM, (eds) GeneReviews\u00ae [Internet]. University of Washington, Seattle. Available at: https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK1269\/"},{"key":"6977_CR11","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1007\/s10038-007-0135-4","volume":"52","author":"P Alfonso","year":"2007","unstructured":"Alfonso P, Aznarez S, Giralt M, Pocovi M, Giraldo P (2007) Mutation analysis and genotype\/phenotype relationships of Gaucher disease patients in Spain. J Hum Genet 52:391\u2013396. https:\/\/doi.org\/10.1007\/s10038-007-0135-4","journal-title":"J Hum Genet"},{"key":"6977_CR12","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1186\/s13023-021-02151-2","volume":"16","author":"T Phetthong","year":"2021","unstructured":"Phetthong T, Tim-Aroon T, Khongkraparn A, Noojarern S, Kuptanon C, Wichajarn K, Sathienkijkanchai A, Suphapeetiporn K, Charoenkwan P, Tantiworawit A, Noentong N, Wattanasirichaigoon D (2021) Gaucher disease: clinical phenotypes and refining GBA mutational spectrum in Thai patients. Orphanet J Rare Dis 16:519. https:\/\/doi.org\/10.1186\/s13023-021-02151-2","journal-title":"Orphanet J Rare Dis"},{"key":"6977_CR13","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1186\/s12881-019-0759-1","volume":"20","author":"J Sheth","year":"2019","unstructured":"Sheth J, Bhavsar R, Mistri M, Pancholi D, Bavdekar A, Dalal A, Ranganath P, Girisha KM, Shukla A, Phadke S, Puri R, Panigrahi I, Kaur A, Muranjan M, Goyal M, Ramadevi R, Shah R, Nampoothiri S, Danda S, Datar C, Kapoor S, Bhatwadekar S, Sheth F (2019) Gaucher disease: single gene molecular characterization of one-hundred Indian patients reveals novel variants and the most prevalent mutation. BMC Med Genet 20:31. https:\/\/doi.org\/10.1186\/s12881-019-0759-1","journal-title":"BMC Med Genet"},{"key":"6977_CR14","doi-asserted-by":"publisher","first-page":"S12","DOI":"10.1002\/ajh.24063","volume":"90","author":"GA Grabowski","year":"2015","unstructured":"Grabowski GA, Zimran A, Ida H (2015) Gaucher disease types 1 and 3: Phenotypic characterization of large populations from the ICGG Gaucher Registry. Am J Hematol 90:S12\u2013S18. https:\/\/doi.org\/10.1002\/ajh.24063","journal-title":"Am J Hematol"},{"key":"6977_CR15","doi-asserted-by":"publisher","first-page":"647","DOI":"10.1016\/j.cell.2007.10.043","volume":"131","author":"GM Griffiths","year":"2007","unstructured":"Griffiths GM (2007) Gaucher disease: forging a new path to the lysosome. Cell 131:647\u2013649. https:\/\/doi.org\/10.1016\/j.cell.2007.10.043","journal-title":"Cell"},{"key":"6977_CR16","doi-asserted-by":"publisher","first-page":"2387","DOI":"10.1093\/hmg\/ddi240","volume":"14","author":"I Ron","year":"2005","unstructured":"Ron I, Horowitz M (2005) ER retention and degradation as the molecular basis underlying Gaucher disease heterogeneity. Hum Mol Genet 14:2387\u20132398. https:\/\/doi.org\/10.1093\/hmg\/ddi240","journal-title":"Hum Mol Genet"},{"key":"6977_CR17","doi-asserted-by":"publisher","first-page":"9177","DOI":"10.1038\/s41598-024-59834-6","volume":"14","author":"T Pornsukjantra","year":"2024","unstructured":"Pornsukjantra T, Saikachain N, Sutjarit N, Khongkrapan A, Tubsuwan A, Bhukhai K, Tim-Aroon T, Anurathapan U, Hongeng S, Asavapanumas N (2024) An increase in ER stress and unfolded protein response in iPSCs-derived neuronal cells from neuronopathic Gaucher disease patients. Sci Rep 14:9177. https:\/\/doi.org\/10.1038\/s41598-024-59834-6","journal-title":"Sci Rep"},{"key":"6977_CR18","doi-asserted-by":"publisher","first-page":"3591","DOI":"10.1111\/febs.14393","volume":"285","author":"ME Gegg","year":"2018","unstructured":"Gegg ME, Schapira AHV (2018) The role of glucocerebrosidase in Parkinson disease pathogenesis. FEBS J 285:3591\u20133603. https:\/\/doi.org\/10.1111\/febs.14393","journal-title":"FEBS J"},{"key":"6977_CR19","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1016\/j.neuron.2017.01.018","volume":"93","author":"E Aflaki","year":"2017","unstructured":"Aflaki E, Westbroek W, Sidransky E (2017) The Complicated Relationship between Gaucher Disease and Parkinsonism: Insights from a Rare Disease. Neuron 93:737\u2013746. https:\/\/doi.org\/10.1016\/j.neuron.2017.01.018","journal-title":"Neuron"},{"key":"6977_CR20","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/j.cell.2011.06.001","volume":"146","author":"JR Mazzulli","year":"2011","unstructured":"Mazzulli JR, Xu YH, Sun Y, Knight AL, McLean PJ, Caldwell GA, Sidransky E, Grabowski GA, Krainc D (2011) Gaucher disease glucocerebrosidase and \u03b1-synuclein form a bidirectional pathogenic loop in synucleinopathies. Cell 146:37\u201352. https:\/\/doi.org\/10.1016\/j.cell.2011.06.001","journal-title":"Cell"},{"key":"6977_CR21","doi-asserted-by":"publisher","first-page":"2628","DOI":"10.1056\/NEJMoa2026834","volume":"383","author":"DB Beck","year":"2020","unstructured":"Beck DB, Ferrada MA, Sikora KA et al (2020) Somatic Mutations in UBA1 and Severe Adult-Onset Autoinflammatory Disease. N Engl J Med 383:2628\u20132638. https:\/\/doi.org\/10.1056\/NEJMoa2026834","journal-title":"N Engl J Med"},{"key":"6977_CR22","doi-asserted-by":"publisher","first-page":"e70087","DOI":"10.1111\/jcmm.70087","volume":"28","author":"CV \u015eoro\u011flu","year":"2024","unstructured":"\u015eoro\u011flu CV, Berkay EG (2024) Old disease\u2014New reflections: Gaucher, immunity, and inflammation. J Cell Mol Med 28:e70087. https:\/\/doi.org\/10.1111\/jcmm.70087","journal-title":"J Cell Mol Med"},{"key":"6977_CR23","doi-asserted-by":"publisher","unstructured":"Cox TM (2001) Gaucher disease: understanding the molecular pathogenesis of sphingolipidoses. J Inherit Metab Dis 24:106\u2013121. https:\/\/doi.org\/10.1023\/a:1012496514170. discussion 87\u201388","DOI":"10.1023\/a:1012496514170"},{"key":"6977_CR24","doi-asserted-by":"publisher","first-page":"13886","DOI":"10.1038\/srep13886","volume":"5","author":"R Mukherjee","year":"2015","unstructured":"Mukherjee R, Kanti Barman P, Kumar Thatoi P, Tripathy R, Kumar Das B, Ravindran B (2015) Non-Classical monocytes display inflammatory features: Validation in Sepsis and Systemic Lupus Erythematous. Sci Rep 5:13886. https:\/\/doi.org\/10.1038\/srep13886","journal-title":"Sci Rep"},{"key":"6977_CR25","doi-asserted-by":"publisher","first-page":"109074","DOI":"10.1016\/j.ymgme.2025.109074","volume":"145","author":"GA Grabowski","year":"2025","unstructured":"Grabowski GA, Kishnani PS, Alcalay RN, Prakalapakorn SG, Rosenbloom BE, Tuason DA, Weinreb NJ (2025) Challenges in Gaucher disease: Perspectives from an expert panel. Mol Genet Metab 145:109074. https:\/\/doi.org\/10.1016\/j.ymgme.2025.109074","journal-title":"Mol Genet Metab"},{"key":"6977_CR26","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1309\/BG5VA8JRDQH1M7HN","volume":"122","author":"LA Boven","year":"2004","unstructured":"Boven LA, van Meurs M, Boot RG, Mehta A, Boon L, Aerts JM, Laman JD (2004) Gaucher Cells Demonstrate a Distinct Macrophage Phenotype and Resemble Alternatively Activated Macrophages. Am J Clin Pathol 122:359\u2013369. https:\/\/doi.org\/10.1309\/BG5VA8JRDQH1M7HN","journal-title":"Am J Clin Pathol"},{"key":"6977_CR27","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1111\/acel.12409","volume":"15","author":"E Aflaki","year":"2016","unstructured":"Aflaki E, Moaven N, Borger DK, Lopez G, Westbroek W, Chae JJ, Marugan J, Patnaik S, Maniwang E, Gonzalez AN, Sidransky E (2016) Lysosomal storage and impaired autophagy lead to inflammasome activation in Gaucher macrophages. Aging Cell 15:77\u201388. https:\/\/doi.org\/10.1111\/acel.12409","journal-title":"Aging Cell"},{"key":"6977_CR28","doi-asserted-by":"publisher","first-page":"3592","DOI":"10.1182\/blood-2019-130032","volume":"134","author":"P Delbini","year":"2019","unstructured":"Delbini P, Ghiandai V, Cappellini MD, Duca L, Nava I, Cassinerio E, Motta I (2019) Evaluation of in Vitro Macrophage Characterization in Gaucher Type 1 (GD1) Patients. Blood 134:3592. https:\/\/doi.org\/10.1182\/blood-2019-130032","journal-title":"Blood"},{"key":"6977_CR29","doi-asserted-by":"publisher","first-page":"952","DOI":"10.1093\/hmg\/ddaf045","volume":"34","author":"G Belinsky","year":"2025","unstructured":"Belinsky G, Ruan J, Fattahi N, Mehta S, Boddupalli CS, Mistry PK, Nair S (2025) Modeling bone marrow microenvironment and hematopoietic dysregulation in Gaucher disease through VavCre mediated Gba deletion. Hum Mol Genet 34:952\u2013966. https:\/\/doi.org\/10.1093\/hmg\/ddaf045","journal-title":"Hum Mol Genet"},{"key":"6977_CR30","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1007\/s10545-011-9308-6","volume":"34","author":"JM Aerts","year":"2011","unstructured":"Aerts JM, Kallemeijn WW, Wegdam W, Joao Ferraz M, van Breemen MJ, Dekker N, Kramer G, Poorthuis BJ, Groener JE, Cox-Brinkman J, Rombach SM, Hollak CE, Linthorst GE, Witte MD, Gold H, van der Marel GA, Overkleeft HS, Boot RG (2011) Biomarkers in the diagnosis of lysosomal storage disorders: proteins, lipids, and inhibodies. J Inherit Metab Dis 34:605\u2013619. https:\/\/doi.org\/10.1007\/s10545-011-9308-6","journal-title":"J Inherit Metab Dis"},{"key":"6977_CR31","doi-asserted-by":"publisher","first-page":"656","DOI":"10.3324\/haematol.2016.155093","volume":"102","author":"E Aflaki","year":"2017","unstructured":"Aflaki E, Borger DK, Grey RJ, Kirby M, Anderson S, Lopez G, Sidransky E (2017) Efferocytosis is impaired in Gaucher macrophages. Haematologica 102:656\u2013665. https:\/\/doi.org\/10.3324\/haematol.2016.155093","journal-title":"Haematologica"},{"key":"6977_CR32","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1016\/j.jbspin.2016.12.002","volume":"85","author":"C Serratrice","year":"2018","unstructured":"Serratrice C, Bensalah N, Penaranda G, Bardin N, Belmatoug N, Masseau A, Rose C, Lidove O, Camou F, Maillot F, Leguy V, Magy-Bertrand N, Marie I, Cherin P, Bengherbia M, Carballo S, Boucraut J, Serratrice J, Berger M, Verrot D (2018) Prevalence of autoantibodies in the course of Gaucher disease type 1: A multicenter study comparing Gaucher disease patients to healthy subjects. Joint Bone Spine 85:71\u201377. https:\/\/doi.org\/10.1016\/j.jbspin.2016.12.002","journal-title":"Joint Bone Spine"},{"issue":"7643","key":"6977_CR33","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1038\/nature21368","volume":"543","author":"MK Pandey","year":"2017","unstructured":"Pandey MK, Burrow TA, Rani R, Martin LJ, Witte D, Setchell KD, Mckay MA, Magnusen AF, Zhang W, Liou B, K\u00f6hl J, Grabowski (2017) Complement drives glucosylceramide accumulation and tissue inflammation in Gaucher disease. Nature 543(7643):108\u2013112. https:\/\/doi.org\/10.1038\/nature21368","journal-title":"Nature"},{"key":"6977_CR34","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1016\/j.immuni.2008.02.001","volume":"28","author":"MG Strainic","year":"2008","unstructured":"Strainic MG, Liu J, Huang D, An F, Lalli PN, Muqim N, Shapiro VS, Dubyak GR, Heeger PS, Medof ME (2008) Locally produced complement fragments C5a and C3a provide both costimulatory and survival signals to naive CD4\u2009+\u2009T cells. Immunity 28:425\u2013435. https:\/\/doi.org\/10.1016\/j.immuni.2008.02.001","journal-title":"Immunity"},{"key":"6977_CR35","doi-asserted-by":"publisher","first-page":"1471","DOI":"10.1056\/NEJM199805143382016","volume":"338","author":"S vom Dahl","year":"1998","unstructured":"vom Dahl S, Niederau C, H\u00e4ussinger D (1998) Loss of vision in Gaucher\u2019s disease and its reversal by enzyme-replacement therapy. N Engl J Med 338:1471\u20131472. https:\/\/doi.org\/10.1056\/NEJM199805143382016","journal-title":"N Engl J Med"},{"key":"6977_CR36","doi-asserted-by":"publisher","first-page":"985","DOI":"10.1002\/hep.23183","volume":"50","author":"LW Poll","year":"2009","unstructured":"Poll LW, vom Dahl S (2009) Hepatic Gaucheroma mimicking focal nodular hyperplasia. Hepatology 50:985\u2013986. https:\/\/doi.org\/10.1002\/hep.23183","journal-title":"Hepatology"},{"key":"6977_CR37","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1016\/j.bcmd.2016.10.018","volume":"68","author":"M Ivanova","year":"2018","unstructured":"Ivanova M, Limgala RP, Changsila E, Kamath R, Ioanou C, Goker-Alpan O (2018) Gaucheromas: When macrophages promote tumor formation and dissemination. Blood Cells Mol Dis 68:100\u2013105. https:\/\/doi.org\/10.1016\/j.bcmd.2016.10.018","journal-title":"Blood Cells Mol Dis"},{"key":"6977_CR38","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1111\/bjh.14915","volume":"179","author":"M Regenboog","year":"2017","unstructured":"Regenboog M, Bohte AE, Akkerman EM, Stoker J, Hollak CEM (2017) Iron storage in liver, bone marrow and splenic Gaucheroma reflects residual disease in type 1 Gaucher disease patients on treatment. Br J Haematol 179:635\u2013647. https:\/\/doi.org\/10.1111\/bjh.14915","journal-title":"Br J Haematol"},{"key":"6977_CR39","doi-asserted-by":"publisher","first-page":"19473","DOI":"10.1073\/pnas.1003308107","volume":"107","author":"PK Mistry","year":"2010","unstructured":"Mistry PK, Liu J, Yang M, Nottoli T, McGrath J, Jain D, Zhang K, Keutzer J, Chuang WL, Mehal WZ, Zhao H, Lin A, Mane S, Liu X, Peng YZ, Li JH, Agrawal M, Zhu LL, Blair HC, Robinson LJ, Iqbal J, Sun L, Zaidi M (2010) Glucocerebrosidase gene-deficient mouse recapitulates Gaucher disease displaying cellular and molecular dysregulation beyond the macrophage. Proc Natl Acad Sci 107:19473\u201319478. https:\/\/doi.org\/10.1073\/pnas.1003308107","journal-title":"Proc Natl Acad Sci"},{"key":"6977_CR40","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1002\/JLB.3RU1018-378RR","volume":"106","author":"L Wang","year":"2019","unstructured":"Wang L, Zhang S, Wu H, Rong X, Guo J (2019) M2b macrophage polarization and its roles in diseases. J Leukoc Biol 106:345\u2013358. https:\/\/doi.org\/10.1002\/JLB.3RU1018-378RR","journal-title":"J Leukoc Biol"},{"key":"6977_CR41","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1016\/j.bcmd.2016.10.009","volume":"68","author":"M Klimkowska","year":"2018","unstructured":"Klimkowska M, Machaczka M, Palmblad J (2018) Aberrant bone marrow vascularization patterns in untreated patients with Gaucher disease type 1. Blood Cells Mol Dis 68:54\u201359. https:\/\/doi.org\/10.1016\/j.bcmd.2016.10.009","journal-title":"Blood Cells Mol Dis"},{"key":"6977_CR42","doi-asserted-by":"publisher","first-page":"86","DOI":"10.15403\/jgld-4752","volume":"32","author":"BA Chis","year":"2023","unstructured":"Chis BA, Ismaiel A, Chis AF (2023) Hepatic, Splenic, and Bone Marrow Gaucheromas: A Case Series and Systematic Literature Review. J Gastrointestin Liver Dis 32:86\u201391. https:\/\/doi.org\/10.15403\/jgld-4752","journal-title":"J Gastrointestin Liver Dis"},{"key":"6977_CR43","doi-asserted-by":"publisher","first-page":"6920","DOI":"10.3390\/jcm11236920","volume":"11","author":"S Linari","year":"2022","unstructured":"Linari S, Castaman G (2022) Hemostatic Abnormalities in Gaucher Disease: Mechanisms and Clinical Implications. J Clin Med 11:6920. https:\/\/doi.org\/10.3390\/jcm11236920","journal-title":"J Clin Med"},{"key":"6977_CR44","doi-asserted-by":"publisher","first-page":"143","DOI":"10.3109\/09537104.2011.597526","volume":"23","author":"M Mitrovic","year":"2012","unstructured":"Mitrovic M, Antic D, Elezovic I, Janic D, Miljic P, Sumarac Z, Nikolic T, Suvajdzic N (2012) Haemostatic abnormalities in treatment-na\u00efve patients with Type 1 Gaucher\u2019s disease. Platelets 23:143\u2013149. https:\/\/doi.org\/10.3109\/09537104.2011.597526","journal-title":"Platelets"},{"key":"6977_CR45","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1016\/j.blre.2016.05.003","volume":"30","author":"M Regenboog","year":"2016","unstructured":"Regenboog M, van Kuilenburg AB, Verheij J, Swinkels DW, Hollak CE (2016) Hyperferritinemia and iron metabolism in Gaucher disease: Potential pathophysiological implications. Blood Rev 30:431\u2013437. https:\/\/doi.org\/10.1016\/j.blre.2016.05.003","journal-title":"Blood Rev"},{"key":"6977_CR46","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1093\/qjmed\/90.1.19","volume":"90","author":"MJ Allen","year":"1997","unstructured":"Allen MJ, Myer BJ, Khokher AM, Rushton N, Cox TM (1997) Pro-inflammatory cytokines and the pathogenesis of Gaucher\u2019s disease: increased release of interleukin-6 and interleukin-10. QJM Int J Med 90:19\u201325. https:\/\/doi.org\/10.1093\/qjmed\/90.1.19","journal-title":"QJM Int J Med"},{"key":"6977_CR47","doi-asserted-by":"publisher","first-page":"7640","DOI":"10.3390\/ijms23147640","volume":"23","author":"L Dupuis","year":"2022","unstructured":"Dupuis L, Chauvet M, Bourdelier E, Dussiot M, Belmatoug N, Le Van Kim C, Ch\u00eane A, Franco M (2022) Phagocytosis of Erythrocytes from Gaucher Patients Induces Phenotypic Modifications in Macrophages, Driving Them toward Gaucher Cells. Int J Mol Sci 23:7640. https:\/\/doi.org\/10.3390\/ijms23147640","journal-title":"Int J Mol Sci"},{"key":"6977_CR48","doi-asserted-by":"publisher","first-page":"121","DOI":"10.14740\/jh543","volume":"8","author":"C Serratrice","year":"2019","unstructured":"Serratrice C, Cherin P, Lidove O, Noel E, Masseau A, Leguy-Seguin V, Jaussaud R, Marie I, Lavigne C, Maillot F (2019) Coagulation Parameters in Adult Patients With Type-1 Gaucher Disease. J Hematol 8:121\u2013124","journal-title":"J Hematol"},{"key":"6977_CR49","doi-asserted-by":"publisher","first-page":"470","DOI":"10.1046\/j.1365-2141.1997.d01-2076.x","volume":"96","author":"CEM Hllak","year":"1997","unstructured":"Hllak CEM, Levi M, Berends F, Aerts JMFG, Van Oers MHJ (1997) Coagulation abnormalities in type 1 Gaucher disease are due to low-grade activation and can be partly restored by enzyme supplementation therapy. Br J Haematol 96:470\u2013476. https:\/\/doi.org\/10.1046\/j.1365-2141.1997.d01-2076.x","journal-title":"Br J Haematol"},{"key":"6977_CR50","doi-asserted-by":"publisher","first-page":"832","DOI":"10.1111\/bjh.12335","volume":"161","author":"M Arends","year":"2013","unstructured":"Arends M, van Dussen L, Biegstraaten M, Hollak CEM (2013) Malignancies and monoclonal gammopathy in Gaucher disease; a systematic review of the literature. Br J Haematol 161:832\u2013842. https:\/\/doi.org\/10.1111\/bjh.12335","journal-title":"Br J Haematol"},{"key":"6977_CR51","doi-asserted-by":"publisher","first-page":"819","DOI":"10.1007\/s10545-018-0142-y","volume":"41","author":"M Regenboog","year":"2018","unstructured":"Regenboog M, van Dussen L, Verheij J, Weinreb NJ, Santosa D, Vom Dahl S, H\u00e4ussinger D, M\u00fcller MN, Canbay A, Rigoldi M, Piperno A, Dinur T, Zimran A, Mistry PK, Salah KY, Belmatoug N, Kuter DJ, Hollak CEM (2018) Hepatocellular carcinoma in Gaucher disease: an international case series. J Inherit Metab Dis 41:819\u2013827. https:\/\/doi.org\/10.1007\/s10545-018-0142-y","journal-title":"J Inherit Metab Dis"},{"key":"6977_CR52","doi-asserted-by":"publisher","first-page":"1337","DOI":"10.1002\/ajh.26675","volume":"97","author":"BE Rosenbloom","year":"2022","unstructured":"Rosenbloom BE, Cappellini MD, Weinreb NJ, Dragosky M, Revel-Vilk S, Batista JL, Sekulic D, Mistry PK (2022) Cancer risk and gammopathies in 2123 adults with Gaucher disease type 1 in the International Gaucher Group Gaucher Registry. Am J Hematol 97:1337\u20131347. https:\/\/doi.org\/10.1002\/ajh.26675","journal-title":"Am J Hematol"},{"key":"6977_CR53","doi-asserted-by":"publisher","first-page":"922","DOI":"10.1111\/ejh.14105","volume":"111","author":"G Giuffrida","year":"2023","unstructured":"Giuffrida G, Markovic U, Condorelli A, Duminuco A, Calafiore V, Conticello C, Romano A, Grasso S, Riccobene C, Ragusa MTV, Esposito B, Nicolosi D, Calagna M, Nardo A, Consoli U, Uccello G, Di Giacomo V, Neri S, Cingari MR, Rod\u00e0 F, Innao V, Fiumara A, Duro G, Zizzo C, Di Raimondo F (2023) Gaucher disease prevalence in 600 patients affected by monoclonal gammopathy of undetermined significance. Eur J Haematol 111:922\u2013929. https:\/\/doi.org\/10.1111\/ejh.14105","journal-title":"Eur J Haematol"},{"key":"6977_CR54","doi-asserted-by":"publisher","first-page":"1247","DOI":"10.3390\/ijms21041247","volume":"21","author":"Y Nguyen","year":"2020","unstructured":"Nguyen Y, Stirnemann J, Lautredoux F, Cador B, Bengherbia M, Yousfi K, Hamroun D, Astudillo L, Billette de Villemeur T, Brassier A, Camou F, Dalbies F, Dobbelaere D, Gaches F, Leguy-Seguin V, Masseau A, Pers YM, Pichard S, Serratrice C, Berger MG, Fantin B, Belmatoug N (2020) Immunoglobulin Abnormalities in Gaucher Disease: an Analysis of 278 Patients Included in the French Gaucher Disease Registry. Int J Mol Sci 21:1247. https:\/\/doi.org\/10.3390\/ijms21041247. On Behalf Of The French Evaluation Of Gaucher Disease Treatment Committee","journal-title":"Int J Mol Sci"},{"key":"6977_CR55","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1056\/NEJMoa1709974","volume":"378","author":"RA Kyle","year":"2018","unstructured":"Kyle RA, Larson DR, Therneau TM, Dispenzieri A, Kumar S, Cerhan JR, Rajkumar SV (2018) Long-Term Follow-up of Monoclonal Gammopathy of Undetermined Significance. N Engl J Med 378:241\u2013249. https:\/\/doi.org\/10.1056\/NEJMoa1709974","journal-title":"N Engl J Med"},{"key":"6977_CR56","doi-asserted-by":"publisher","first-page":"4569","DOI":"10.1182\/blood-2004-12-4672","volume":"105","author":"BE Rosenbloom","year":"2005","unstructured":"Rosenbloom BE, Weinreb NJ, Zimran A, Kacena KA, Charrow J, Ward E (2005) Gaucher disease and cancer incidence: a study from the Gaucher Registry. Blood 105:4569\u20134572. https:\/\/doi.org\/10.1182\/blood-2004-12-4672","journal-title":"Blood"},{"key":"6977_CR57","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1016\/j.bcmd.2005.08.004","volume":"36","author":"M de Fost","year":"2006","unstructured":"de Fost M, Vom Dahl S, Weverling GJ, Brill N, Brett S, H\u00e4ussinger D, Hollak CE (2006) Increased incidence of cancer in adult Gaucher disease in Western Europe. Blood Cells Mol Dis 36:53\u201358. https:\/\/doi.org\/10.1016\/j.bcmd.2005.08.004","journal-title":"Blood Cells Mol Dis"},{"key":"6977_CR58","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1002\/ajh.21362","volume":"84","author":"TH Taddei","year":"2009","unstructured":"Taddei TH, Kacena KA, Yang M, Yang R, Malhotra A, Boxer M, Aleck KA, Rennert G, Pastores GM, Mistry PK (2009) The underrecognized progressive nature of N370S Gaucher disease and assessment of cancer risk in 403 patients. Am J Hematol 84:208\u2013214. https:\/\/doi.org\/10.1002\/ajh.21362","journal-title":"Am J Hematol"},{"key":"6977_CR59","doi-asserted-by":"publisher","first-page":"e70079","DOI":"10.1002\/hem3.70079","volume":"9","author":"S Mor\u00e8","year":"2025","unstructured":"Mor\u00e8 S, Federici I, Bossi A et al (2025) Prevalence of type I Gaucher disease in patients with smoldering or multiple myeloma: Results from the prospective, observational CHAGAL study. HemaSphere 9:e70079. https:\/\/doi.org\/10.1002\/hem3.70079","journal-title":"HemaSphere"},{"key":"6977_CR60","doi-asserted-by":"publisher","first-page":"4858","DOI":"10.3390\/cancers14194858","volume":"14","author":"P Dubot","year":"2022","unstructured":"Dubot P, Astudillo L, Therville N, Carri\u00e9 L, Pettazzoni M, Cheillan D, Stirnemann J, Levade T, Andrieu-Abadie N, Sabourdy F (2022) Potential Role of Sphingolipidoses-Associated Lysosphingolipids in Cancer. Cancers 14:4858. https:\/\/doi.org\/10.3390\/cancers14194858","journal-title":"Cancers"},{"key":"6977_CR61","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1056\/NEJMoa1508808","volume":"374","author":"S Nair","year":"2016","unstructured":"Nair S, Branagan AR, Liu J, Boddupalli CS, Mistry PK, Dhodapkar MV (2016) Clonal Immunoglobulin against Lysolipids in the Origin of Myeloma. N Engl J Med 374:555\u2013561. https:\/\/doi.org\/10.1056\/NEJMoa1508808","journal-title":"N Engl J Med"},{"key":"6977_CR62","doi-asserted-by":"publisher","first-page":"1256","DOI":"10.1182\/blood-2014-09-600270","volume":"125","author":"S Nair","year":"2015","unstructured":"Nair S, Boddupalli CS, Verma R, Liu J, Yang R, Pastores GM, Mistry PK, Dhodapkar MV (2015) Type II NKT-TFH cells against Gaucher lipids regulate B-cell immunity and inflammation. Blood 125:1256\u20131271. https:\/\/doi.org\/10.1182\/blood-2014-09-600270","journal-title":"Blood"},{"key":"6977_CR63","doi-asserted-by":"publisher","first-page":"1200","DOI":"10.1182\/blood-2014-12-617514","volume":"125","author":"M Salio","year":"2015","unstructured":"Salio M, Cerundolo V (2015) NKT-dependent B-cell activation in Gaucher disease. Blood 125:1200\u20131202. https:\/\/doi.org\/10.1182\/blood-2014-12-617514","journal-title":"Blood"},{"key":"6977_CR64","doi-asserted-by":"publisher","first-page":"1748","DOI":"10.4081\/itjm.2024.1748","volume":"18","author":"A De Vivo","year":"2024","unstructured":"De Vivo A, Marconi G, Tumedei N, Luicchini E, Finazzi MC, Burgo IM, Forni GL, Linari S (2024) Expert consensus guideline on the diagnosis of type 1 Gaucher disease in adult patients. Ital J Med 18:1748. https:\/\/doi.org\/10.4081\/itjm.2024.1748","journal-title":"Ital J Med"},{"key":"6977_CR65","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1007\/s00431-003-1362-0","volume":"163","author":"GA Grabowski","year":"2004","unstructured":"Grabowski GA, Andria G, Baldellou A, Campbell PE, Charrow J, Cohen IJ, Harris CM, Kaplan P, Mengel E, Pocovi M, Vellodi A (2004) Pediatric non-neuronopathic Gaucher disease: presentation, diagnosis and assessment. Consensus statements. Eur J Pediatr 163:58\u201366. https:\/\/doi.org\/10.1007\/s00431-003-1362-0","journal-title":"Eur J Pediatr"},{"key":"6977_CR66","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1016\/j.bcmd.2016.10.002","volume":"68","author":"NJ Weinreb","year":"2018","unstructured":"Weinreb NJ, Barbouth DS, Lee RE (2018) Causes of death in 184 patients with type 1 Gaucher disease from the United States who were never treated with enzyme replacement therapy. Blood Cells Mol Dis 68:211\u2013217. https:\/\/doi.org\/10.1016\/j.bcmd.2016.10.002","journal-title":"Blood Cells Mol Dis"},{"key":"6977_CR67","doi-asserted-by":"publisher","first-page":"472","DOI":"10.1002\/ajh.21721","volume":"85","author":"P Stein","year":"2010","unstructured":"Stein P, Yu H, Jain D, Mistry PK (2010) Hyperferritinemia and Iron Overload in Type 1 Gaucher Disease. Am J Hematol 85:472\u2013476. https:\/\/doi.org\/10.1002\/ajh.21721","journal-title":"Am J Hematol"},{"issue":"1","key":"6977_CR68","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1186\/s13023-023-02844-w","volume":"18","author":"J Feng","year":"2023","unstructured":"Feng J, Gao Z, Shi Z, Wang Y, Li S (2023) Patient-reported outcomes in Gaucher\u2019s disease: a systematic review. Orphanet J Rare Dis 18(1):244. https:\/\/doi.org\/10.1186\/s13023-023-02844-w","journal-title":"Orphanet J Rare Dis"},{"key":"6977_CR69","doi-asserted-by":"publisher","first-page":"2926","DOI":"10.3390\/jcm13102926","volume":"13","author":"M Bengherbia","year":"2024","unstructured":"Bengherbia M, Berger M, Hivert B, Rigaudier F, Bracoud L, Vaeterlein O, Yousfi K, Maric M, Malcles M, Belmatoug N (2024) A Real-World Investigation of MRI Changes in Bone in Patients with Type 1 Gaucher Disease Treated with Velaglucerase Alfa: The EIROS Study. J Clin Med 13:2926. https:\/\/doi.org\/10.3390\/jcm13102926","journal-title":"J Clin Med"},{"key":"6977_CR70","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1097\/MD.0b013e3182057be4","volume":"90","author":"PB Deegan","year":"2011","unstructured":"Deegan PB, Pavlova E, Tindall J, Stein PE, Bearcroft P, Mehta A, Hughes D, Wraith JE, Cox TM (2011) Osseous manifestations of adult Gaucher disease in the era of enzyme replacement therapy. Med (Baltim) 90:52\u201360. https:\/\/doi.org\/10.1097\/MD.0b013e3182057be4","journal-title":"Med (Baltim)"},{"key":"6977_CR71","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1007\/s10354-010-0841-y","volume":"160","author":"P Mikosch","year":"2010","unstructured":"Mikosch P, Hughes D (2010) An overview on bone manifestations in Gaucher disease. Wien Med Wochenschr 160:609\u2013624. https:\/\/doi.org\/10.1007\/s10354-010-0841-y","journal-title":"Wien Med Wochenschr"},{"key":"6977_CR72","doi-asserted-by":"publisher","first-page":"580","DOI":"10.1016\/S0140-6736(05)79295-3","volume":"352","author":"GM Pastores","year":"1998","unstructured":"Pastores GM, Miller A (1998) Pulmonary hypertension in Gaucher\u2019s disease. Lancet 352:580. https:\/\/doi.org\/10.1016\/S0140-6736(05)79295-3","journal-title":"Lancet"},{"key":"6977_CR73","doi-asserted-by":"publisher","first-page":"837","DOI":"10.1053\/j.ajkd.2005.07.042","volume":"46","author":"R Becker-Cohen","year":"2005","unstructured":"Becker-Cohen R, Elstein D, Abrahamov A, Algur N, Rudensky B, Hadas-Halpern I, Zimran A, Frishberg Y (2005) A comprehensive assessment of renal function in patients with Gaucher disease. Am J Kidney Dis Off J Natl Kidney Found 46:837\u2013844. https:\/\/doi.org\/10.1053\/j.ajkd.2005.07.042","journal-title":"Am J Kidney Dis Off J Natl Kidney Found"},{"key":"6977_CR74","doi-asserted-by":"publisher","first-page":"3897","DOI":"10.1007\/s00415-024-12439-5","volume":"271","author":"G Imbalzano","year":"2024","unstructured":"Imbalzano G, Ledda C, Romagnolo A, Covolo A, Lopiano L, Artusi CA (2024) Neurological symptoms in adults with Gaucher disease: a systematic review. J Neurol 271:3897\u20133907. https:\/\/doi.org\/10.1007\/s00415-024-12439-5","journal-title":"J Neurol"},{"key":"6977_CR75","doi-asserted-by":"publisher","first-page":"526","DOI":"10.1038\/s41582-024-00999-z","volume":"20","author":"E Hertz","year":"2024","unstructured":"Hertz E, Chen Y, Sidransky E (2024) Gaucher disease provides a unique window into Parkinson disease pathogenesis. Nat Rev Neurol 20:526\u2013540. https:\/\/doi.org\/10.1038\/s41582-024-00999-z","journal-title":"Nat Rev Neurol"},{"key":"6977_CR76","doi-asserted-by":"publisher","first-page":"5842","DOI":"10.3390\/ijms23105842","volume":"23","author":"ML Furderer","year":"2022","unstructured":"Furderer ML, Hertz E, Lopez GJ, Sidransky E (2022) Neuropathological Features of Gaucher Disease and Gaucher Disease with Parkinsonism. Int J Mol Sci 23:5842. https:\/\/doi.org\/10.3390\/ijms23105842","journal-title":"Int J Mol Sci"},{"key":"6977_CR77","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1016\/j.ymgme.2014.11.008","volume":"114","author":"K Weiss","year":"2015","unstructured":"Weiss K, Gonzalez A, Lopez G, Pedoeim L, Groden C, Sidransky E (2015) The Clinical Management of Type 2 Gaucher Disease. Mol Genet Metab 114:110\u2013122. https:\/\/doi.org\/10.1016\/j.ymgme.2014.11.008","journal-title":"Mol Genet Metab"},{"key":"6977_CR78","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1016\/j.ymgme.2016.12.001","volume":"120","author":"A El-Beshlawy","year":"2017","unstructured":"El-Beshlawy A, Tylki-Szymanska A, Vellodi A, Belmatoug N, Grabowski GA, Kolodny EH, Batista JL, Cox GF, Mistry PK (2017) Long-term hematological, visceral, and growth outcomes in children with Gaucher disease type 3 treated with imiglucerase in the International Collaborative Gaucher Group Gaucher Registry. Mol Genet Metab 120:47\u201356. https:\/\/doi.org\/10.1016\/j.ymgme.2016.12.001","journal-title":"Mol Genet Metab"},{"key":"6977_CR79","doi-asserted-by":"publisher","unstructured":"Tenenbaum A, Revel-Vilk S, Gazit S, Roimi M, Gill A, Gilboa D, Paltiel O, Manor O, Shalev V, Chodick G (2024) A machine learning model for early diagnosis of type 1 Gaucher disease using real-life data. J Clin Epidemiol 175. https:\/\/doi.org\/10.1016\/j.jclinepi.2024.111517","DOI":"10.1016\/j.jclinepi.2024.111517"},{"key":"6977_CR80","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1111\/ejh.12596","volume":"96","author":"I Motta","year":"2016","unstructured":"Motta I, Filocamo M, Poggiali E, Stroppiano M, Dragani A, Consonni D, Barcellini W, Gaidano G, Facchini L, Specchia G, Cappellini MD, Splenomegaly Gaucher Disease study group (2016) A multicentre observational study for early diagnosis of Gaucher disease in patients with Splenomegaly and\/or Thrombocytopenia. Eur J Haematol 96:352\u2013359. https:\/\/doi.org\/10.1111\/ejh.12596","journal-title":"Eur J Haematol"},{"key":"6977_CR81","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1002\/ajh.20908","volume":"82","author":"PK Mistry","year":"2007","unstructured":"Mistry PK, Sadan S, Yang R, Yee J, Yang M (2007) Consequences of diagnostic delays in type 1 Gaucher disease: the need for greater awareness among hematologists-oncologists and an opportunity for early diagnosis and intervention. Am J Hematol 82:697\u2013701. https:\/\/doi.org\/10.1002\/ajh.20908","journal-title":"Am J Hematol"},{"key":"6977_CR82","doi-asserted-by":"publisher","DOI":"10.1186\/s13023-026-04209-5","author":"DPP Arag\u00f3n","year":"2026","unstructured":"Arag\u00f3n DPP, Collin-Histed T, Abdelwahab M, Espinosa JV, Chertkoff R, Balzekiene A, Pacey J (2026) Exploring delayed diagnosis in Gaucher disease: insights from a community survey and potential solutions. Orphanet J Rare Dis. https:\/\/doi.org\/10.1186\/s13023-026-04209-5","journal-title":"Orphanet J Rare Dis"},{"key":"6977_CR83","doi-asserted-by":"publisher","unstructured":"Mistry PK, Cappellini MD, Lukina E, Ozsan H, Mach Pascual S, Rosenbaum H, Helena Solano M, Spigelman Z, Villarrubia J, Watman NP, Massenkeil G (2011) Consensus Conference: A reappraisal of Gaucher disease - diagnosis and disease management algorithms. Am J Hematol 86:110\u2013115. https:\/\/doi.org\/10.1002\/ajh.21888","DOI":"10.1002\/ajh.21888"},{"key":"6977_CR84","doi-asserted-by":"publisher","first-page":"2594","DOI":"10.1038\/s41598-021-82296-z","volume":"11","author":"I Motta","year":"2021","unstructured":"Motta I, Consonni D, Stroppiano M, Benedetto C, Cassinerio E, Tappino B, Ranalli P, Borin L, Facchini L, Patriarca A, Barcellini W, Lanza F, Filocamo M, Cappellini MD, Splenomegaly Gaucher group (2021) Predicting the probability of Gaucher disease in subjects with splenomegaly and thrombocytopenia. Sci Rep 11:2594. https:\/\/doi.org\/10.1038\/s41598-021-82296-z","journal-title":"Sci Rep"},{"key":"6977_CR85","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1186\/s13023-023-02868-2","volume":"18","author":"A Wilson","year":"2023","unstructured":"Wilson A, Chiorean A, Aguiar M, Sekulic D, Pavlick P, Shah N, Sniderman King L, G\u00e9nin M, Rollot M, Blanchon M, Gosset S, Montmerle M, Molony C, Dumitriu A (2023) Development of a rare disease algorithm to identify persons at risk of Gaucher disease using electronic health records in the United States. Orphanet J Rare Dis 18:280. https:\/\/doi.org\/10.1186\/s13023-023-02868-2","journal-title":"Orphanet J Rare Dis"},{"key":"6977_CR86","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1016\/j.ymgme.2021.12.009","volume":"135","author":"PS Kishnani","year":"2022","unstructured":"Kishnani PS, Al-Hertani W, Balwani M, G\u00f6ker-Alpan \u00d6, Lau HA, Wasserstein M, Weinreb NJ, Grabowski G (2022) Screening, patient identification, evaluation, and treatment in patients with Gaucher disease: Results from a Delphi consensus. Mol Genet Metab 135:154\u2013162. https:\/\/doi.org\/10.1016\/j.ymgme.2021.12.009","journal-title":"Mol Genet Metab"},{"key":"6977_CR87","doi-asserted-by":"publisher","first-page":"781","DOI":"10.3324\/haematol.2022.280759","volume":"107","author":"R Invernizzi","year":"2022","unstructured":"Invernizzi R (2022) Images from the Haematologica Atlas of Hematologic Cytology: precursor lymphoid neoplasms, cytochemistry and immunocytochemistry. Haematologica 107:781. https:\/\/doi.org\/10.3324\/haematol.2022.280759","journal-title":"Haematologica"},{"key":"6977_CR88","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1016\/j.ejim.2022.11.028","volume":"108","author":"MD Cappellini","year":"2023","unstructured":"Cappellini MD, Motta I, Barbato A, Giuffrida G, Manna R, Carubbi F, Giona F (2023) Similarities and differences between Gaucher disease and acid sphingomyelinase deficiency: An algorithm to support the diagnosis. Eur J Intern Med 108:81\u201384. https:\/\/doi.org\/10.1016\/j.ejim.2022.11.028","journal-title":"Eur J Intern Med"},{"key":"6977_CR89","doi-asserted-by":"publisher","first-page":"442","DOI":"10.1186\/s13023-022-02573-6","volume":"17","author":"A Dardis","year":"2022","unstructured":"Dardis A, Michelakakis H, Rozenfeld P, Fumic K, Wagner J, Pavan E, Fuller M, Revel-Vilk S, Hughes D, Cox T, Aerts J, International Working Group of Gaucher Disease (IWGGD) (2022) Patient centered guidelines for the laboratory diagnosis of Gaucher disease type 1. Orphanet J Rare Dis 17:442. https:\/\/doi.org\/10.1186\/s13023-022-02573-6","journal-title":"Orphanet J Rare Dis"},{"key":"6977_CR90","doi-asserted-by":"publisher","first-page":"570","DOI":"10.1002\/ajh.25752","volume":"95","author":"G Marchi","year":"2020","unstructured":"Marchi G, Nascimbeni F, Motta I et al (2020) Hyperferritinemia and diagnosis of type 1 Gaucher disease. Am J Hematol 95:570\u2013576. https:\/\/doi.org\/10.1002\/ajh.25752","journal-title":"Am J Hematol"},{"key":"6977_CR91","doi-asserted-by":"publisher","first-page":"26","DOI":"10.3390\/ijns6020026","volume":"6","author":"SJ Moat","year":"2020","unstructured":"Moat SJ, George RS, Carling RS (2020) Use of Dried Blood Spot Specimens to Monitor Patients with Inherited Metabolic Disorders. Int J Neonatal Screen 6:26. https:\/\/doi.org\/10.3390\/ijns6020026","journal-title":"Int J Neonatal Screen"},{"key":"6977_CR92","doi-asserted-by":"publisher","first-page":"e2026016","DOI":"10.4084\/MJHID.2026.016","volume":"18","author":"A Costa","year":"2026","unstructured":"Costa A, Perra D, Mulas O, Podda L, Longu F, Fozza C, Palmas A, Curreli L, Cappellini MD, Zizzo C, Caocci G (2026) Early Diagnosis of Gaucher Disease and ASMD in Sardinia: the ICHNOS Project. Mediterr J Hematol Infect Dis 18:e2026016. https:\/\/doi.org\/10.4084\/MJHID.2026.016","journal-title":"Mediterr J Hematol Infect Dis"},{"key":"6977_CR93","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1016\/S1096-7192(02)00117-8","volume":"76","author":"E Orvisky","year":"2002","unstructured":"Orvisky E, Park JK, LaMarca ME, Ginns EI, Martin BM, Tayebi N, Sidransky E (2002) Glucosylsphingosine accumulation in tissues from patients with Gaucher disease: correlation with phenotype and genotype. Mol Genet Metab 76:262\u2013270. https:\/\/doi.org\/10.1016\/S1096-7192(02)00117-8","journal-title":"Mol Genet Metab"},{"key":"6977_CR94","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1186\/s13023-024-03444-y","volume":"20","author":"A Zimran","year":"2025","unstructured":"Zimran A, Revel-Vilk S, Dinur T, Istaiti M, Botha J, Lukina E, Giraldo P, Deegan P, Dahl SV (2025) Evaluation of Lyso-Gb1 as a biomarker for Gaucher disease treatment outcomes using data from the Gaucher Outcome Survey. Orphanet J Rare Dis 20:43. https:\/\/doi.org\/10.1186\/s13023-024-03444-y","journal-title":"Orphanet J Rare Dis"},{"key":"6977_CR95","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1016\/j.cca.2020.10.007","volume":"511","author":"J Beasley","year":"2020","unstructured":"Beasley J, McCaw P, Zhang H, Young SP, Stiles AR (2020) Combined analysis of plasma or serum glucosylsphingosine and globotriaosylsphingosine by UPLC-MS\/MS. Clin Chim Acta 511:132\u2013137. https:\/\/doi.org\/10.1016\/j.cca.2020.10.007","journal-title":"Clin Chim Acta"},{"key":"6977_CR96","doi-asserted-by":"publisher","first-page":"1156","DOI":"10.1002\/ajh.26276","volume":"96","author":"PK Mistry","year":"2021","unstructured":"Mistry PK, Lukina E, Ben Turkia H, Shankar SP, Baris Feldman H, Ghosn M, Mehta A, Packman S, Lau H, Petakov M, Assouline S, Balwani M, Danda S, Hadjiev E, Ortega A, Foster MC, Gaemers SJM, Peterschmitt MJ (2021) Clinical outcomes after 4.5 years of eliglustat therapy for Gaucher disease type 1: Phase 3 ENGAGE trial final results. Am J Hematol 96:1156\u20131165. https:\/\/doi.org\/10.1002\/ajh.26276","journal-title":"Am J Hematol"},{"key":"6977_CR97","doi-asserted-by":"publisher","first-page":"e118","DOI":"10.1182\/blood-2011-05-352971","volume":"118","author":"N Dekker","year":"2011","unstructured":"Dekker N, van Dussen L, Hollak CE, Overkleeft H, Scheij S, Ghauharali K, van Breemen MJ, Ferraz MJ, Groener JE, Maas M, Wijburg FA, Speijer D, Tylki-Szymanska A, Mistry PK, Boot RG, Aerts JM (2011) Elevated plasma glucosylsphingosine in Gaucher disease: relation to phenotype, storage cell markers, and therapeutic response. Blood 118:e118\u2013e127. https:\/\/doi.org\/10.1182\/blood-2011-05-352971","journal-title":"Blood"},{"key":"6977_CR98","doi-asserted-by":"publisher","first-page":"e79732","DOI":"10.1371\/journal.pone.0079732","volume":"8","author":"A Rolfs","year":"2013","unstructured":"Rolfs A, Giese AK, Grittner U, Mascher D, Elstein D, Zimran A, B\u00f6ttcher T, Lukas J, H\u00fcbner R, G\u00f6lnitz U, R\u00f6hle A, Dudesek A, Meyer W, Wittstock M, Mascher H (2013) Glucosylsphingosine Is a Highly Sensitive and Specific Biomarker for Primary Diagnostic and Follow-Up Monitoring in Gaucher Disease in a Non-Jewish, Caucasian Cohort of Gaucher Disease Patients. PLoS ONE 8:e79732. https:\/\/doi.org\/10.1371\/journal.pone.0079732","journal-title":"PLoS ONE"},{"key":"6977_CR99","doi-asserted-by":"publisher","first-page":"1292","DOI":"10.1016\/j.bbapap.2006.05.009","volume":"1764","author":"L Quintana","year":"2006","unstructured":"Quintana L, Monasterio A, Escuredo K, del Amo J, Alfonso P, Elortza F, Santa Cruz S, Sim\u00f3n L, Mart\u00ednez A, Giraldo P, Pocov\u00ed M, Castrillo JL (2006) Identification of chitotriosidase isoforms in plasma of Gaucher disease patients by two dimensional gel electrophoresis. Biochim Biophys Acta 1764:1292\u20131298. https:\/\/doi.org\/10.1016\/j.bbapap.2006.05.009","journal-title":"Biochim Biophys Acta"},{"key":"6977_CR100","doi-asserted-by":"publisher","first-page":"1804","DOI":"10.1016\/j.clinbiochem.2013.09.006","volume":"46","author":"P Ir\u00fan","year":"2013","unstructured":"Ir\u00fan P, Alfonso P, Aznarez S, Giraldo P, Pocovi M (2013) Chitotriosidase variants in patients with Gaucher disease. Implications for diagnosis and therapeutic monitoring. Clin Biochem 46:1804\u20131807. https:\/\/doi.org\/10.1016\/j.clinbiochem.2013.09.006","journal-title":"Clin Biochem"},{"key":"6977_CR101","doi-asserted-by":"publisher","first-page":"1425","DOI":"10.1016\/j.gim.2022.03.021","volume":"24","author":"M Wasserstein","year":"2022","unstructured":"Wasserstein M, Lachmann R, Hollak C, Arash-Kaps L, Barbato A, Gallagher RC, Giugliani R, Guelbert NB, Ikezoe T, Lidove O, Mabe P, Mengel E, Scarpa M, Senates E, Tchan M, Villarrubia J, Chen Y, Furey S, Thurberg BL, Zaher A, Kumar M (2022) A randomized, placebo-controlled clinical trial evaluating olipudase alfa enzyme replacement therapy for chronic acid sphingomyelinase deficiency (ASMD) in adults: One-year results. Genet Med 24:1425\u20131436. https:\/\/doi.org\/10.1016\/j.gim.2022.03.021","journal-title":"Genet Med"},{"key":"6977_CR102","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1016\/j.ymgmr.2016.06.008","volume":"9","author":"NV Ortiz-Cabrera","year":"2016","unstructured":"Ortiz-Cabrera NV, Gallego-Merlo J, V\u00e9lez-Monsalve C, de Nicolas R, Mas SF, Ayuso C, Trujillo-Tiebas MJ (2016) Nine-year experience in Gaucher disease diagnosis at the Spanish reference center Fundaci\u00f3n Jim\u00e9nez D\u00edaz. Mol Genet Metab Rep 9:79\u201385. https:\/\/doi.org\/10.1016\/j.ymgmr.2016.06.008","journal-title":"Mol Genet Metab Rep"},{"key":"6977_CR103","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1016\/j.jmoldx.2017.05.005","volume":"19","author":"S Zampieri","year":"2017","unstructured":"Zampieri S, Cattarossi S, Bembi B, Dardis A (2017) GBA Analysis in Next-Generation Era: Pitfalls, Challenges, and Possible Solutions. J Mol Diagn 19:733\u2013741. https:\/\/doi.org\/10.1016\/j.jmoldx.2017.05.005","journal-title":"J Mol Diagn"},{"key":"6977_CR104","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1038\/s41598-020-80564-y","volume":"11","author":"JM den Heijer","year":"2021","unstructured":"den Heijer JM, Schmitz A, Lansbury P, Cullen VC, Hilt DC, Bonifati V, Groeneveld GJ (2021) False negatives in GBA1 sequencing due to polymerase dependent allelic imbalance. Sci Rep 11:161. https:\/\/doi.org\/10.1038\/s41598-020-80564-y","journal-title":"Sci Rep"},{"key":"6977_CR105","doi-asserted-by":"publisher","first-page":"488","DOI":"10.1016\/j.jmoldx.2020.01.010","volume":"22","author":"A Zanetti","year":"2022","unstructured":"Zanetti A, D\u2019Avanzo F, Bertoldi L, Zampieri G, Feltrin E, De Pascale F, Rampazzo A, Forzan M, Valle G, Tomanin R (2022) Setup and Validation of a Targeted Next-Generation Sequencing Approach for the Diagnosis of Lysosomal Storage Disorders. J Mol Diagn 22:488\u2013502. https:\/\/doi.org\/10.1016\/j.jmoldx.2020.01.010","journal-title":"J Mol Diagn"},{"key":"6977_CR106","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1016\/j.ymgme.2016.10.008","volume":"119","author":"G Amico","year":"2016","unstructured":"Amico G, Grossi S, Vijzelaar R, Lanza F, Mazzotti R, Corsolini F, Ketema M, Filocamo M (2016) MLPA-based approach for initial and simultaneous detection of GBA deletions and recombinant alleles in patients affected by Gaucher Disease. Mol Genet Metab 119:329\u2013337. https:\/\/doi.org\/10.1016\/j.ymgme.2016.10.008","journal-title":"Mol Genet Metab"},{"key":"6977_CR107","doi-asserted-by":"publisher","first-page":"2782","DOI":"10.3390\/jcm13102782","volume":"13","author":"P Deegan","year":"2024","unstructured":"Deegan P, Lau H, Elstein D, Fernandez-Sasso D, Giraldo P, Hughes D, Zimran A, Istaiti M, Gadir N, Botha J, Revel-Vilk S, GOS Study Group (2024) Long-Term Treatment of Gaucher Disease with Velaglucerase Alfa in ERT-Na\u00efve Patients from the Gaucher Outcome Survey (GOS) Registry. J Clin Med 13:2782. https:\/\/doi.org\/10.3390\/jcm13102782","journal-title":"J Clin Med"},{"key":"6977_CR108","doi-asserted-by":"publisher","unstructured":"Weinreb NJ, Camelo JS Jr, Charrow J, McClain MR, Mistry P, Belmatoug N, International Collaborative Gaucher Group (ICGG) Gaucher Registry (NCT00358943) investigators (2021) Gaucher disease type 1 patients from the ICGG Gaucher Registry sustain initial clinical improvements during twenty years of imiglucerase treatment. Mol Genet Metab 132:100\u2013111. https:\/\/doi.org\/10.1016\/j.ymgme.2020.12.295","DOI":"10.1016\/j.ymgme.2020.12.295"},{"key":"6977_CR109","doi-asserted-by":"publisher","first-page":"1500","DOI":"10.1002\/ajh.27347","volume":"99","author":"PK Mistry","year":"2024","unstructured":"Mistry PK, Balwani M, Charrow J, Lorber J, Niederau C, Carwile JL, Oliveira-Dos-Santos A, Perichon MG, Uslu Cil S, Kishnani PS (2024) Long-term effectiveness of eliglustat treatment: A real-world analysis from the International Collaborative Gaucher Group Gaucher Registry. Am J Hematol 99:1500\u20131510. https:\/\/doi.org\/10.1002\/ajh.27347","journal-title":"Am J Hematol"},{"key":"6977_CR110","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/j.ejim.2016.07.011","volume":"37","author":"N Belmatoug","year":"2017","unstructured":"Belmatoug N, Di Rocco M, Fraga C, Giraldo P, Hughes D, Lukina E, Maison-Blanche P, Merkel M, Niederau C, Pl\u04e7ckinger U, Richter J, Stulnig TM, Vom Dahl S, Cox TM (2017) Management and monitoring recommendations for the use of eliglustat in adults with type 1 Gaucher disease in Europe. Eur J Intern Med 37:25\u201332. https:\/\/doi.org\/10.1016\/j.ejim.2016.07.011","journal-title":"Eur J Intern Med"},{"key":"6977_CR111","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1097\/GIM.0b013e31818e2c19","volume":"11","author":"GA Grabowski","year":"2009","unstructured":"Grabowski GA, Kacena K, Cole JA, Hollak CE, Zhang L, Yee J, Mistry PK, Zimran A, Charrow J, vom Dahl S (2009) Dose-response relationships for enzyme replacement therapy with imiglucerase\/alglucerase in patients with Gaucher disease type 1. Genet Med Off J Am Coll Med Genet 11:92\u2013100. https:\/\/doi.org\/10.1097\/GIM.0b013e31818e2c19","journal-title":"Genet Med Off J Am Coll Med Genet"},{"key":"6977_CR112","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1016\/j.ymgme.2008.12.015","volume":"96","author":"PS Kishnani","year":"2009","unstructured":"Kishnani PS, DiRocco M, Kaplan P, Mehta A, Pastores GM, Smith SE, Puga AC, Lemay RM, Weinreb NJ (2009) A randomized trial comparing the efficacy and safety of imiglucerase (Cerezyme) infusions every 4 weeks versus every 2 weeks in the maintenance therapy of adult patients with Gaucher disease type 1. Mol Genet Metab 96:164\u2013170. https:\/\/doi.org\/10.1016\/j.ymgme.2008.12.015","journal-title":"Mol Genet Metab"},{"key":"6977_CR113","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1002\/ajh.23382","volume":"88","author":"H Ben Turkia","year":"2013","unstructured":"Ben Turkia H, Gonzalez DE, Barton NW, Zimran A, Kabra M, Lukina EA, Giraldo P, Kisinovsky I, Bavdekar A, Ben Dridi MF, Gupta N, Kishnani PS, Sureshkumar EK, Wang N, Crombez E, Bhirangi K, Mehta A (2013) Velaglucerase alfa enzyme replacement therapy compared with imiglucerase in patients with Gaucher disease. Am J Hematol 88:179\u2013184. https:\/\/doi.org\/10.1002\/ajh.23382","journal-title":"Am J Hematol"},{"key":"6977_CR114","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1038\/gim.2013.154","volume":"16","author":"GM Pastores","year":"2014","unstructured":"Pastores GM, Rosenbloom B, Weinreb N, Goker-Alpan O, Grabowski G, Cohn GM, Zahrieh D (2014) A multicenter open-label treatment protocol (HGT-GCB-058) of velaglucerase alfa enzyme replacement therapy in patients with Gaucher disease type 1: safety and tolerability. Genet Med Off J Am Coll Med Genet 16:359\u2013366. https:\/\/doi.org\/10.1038\/gim.2013.154","journal-title":"Genet Med Off J Am Coll Med Genet"},{"key":"6977_CR115","doi-asserted-by":"publisher","first-page":"5767","DOI":"10.1182\/blood-2011-07-366955","volume":"118","author":"A Zimran","year":"2011","unstructured":"Zimran A, Brill-Almon E, Chertkoff R, Petakov M, Blanco-Favela F, Mu\u00f1oz ET, Solorio-Meza SE, Amato D, Duran G, Giona F, Heitner R, Rosenbaum H, Giraldo P, Mehta A, Park G, Phillips M, Elstein D, Altarescu G, Szleifer M, Hashmueli S, Aviezer D (2011) Pivotal trial with plant cell\u2013expressed recombinant glucocerebrosidase, taliglucerase alfa, a novel enzyme replacement therapy for Gaucher disease. Blood 118:5767\u20135773. https:\/\/doi.org\/10.1182\/blood-2011-07-366955","journal-title":"Blood"},{"key":"6977_CR116","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1016\/j.bcmd.2014.05.004","volume":"53","author":"GM Pastores","year":"2014","unstructured":"Pastores GM, Petakov M, Giraldo P, Rosenbaum H, Szer J, Deegan PB, Amato DJ, Mengel E, Tan ES, Chertkoff R, Brill-Almon E, Zimran A (2014) A Phase 3, multicenter, open-label, switchover trial to assess the safety and efficacy of taliglucerase alfa, a plant cell-expressed recombinant human glucocerebrosidase, in adult and pediatric patients with Gaucher disease previously treated with imiglucerase. Blood Cells Mol Dis 53:253\u2013260. https:\/\/doi.org\/10.1016\/j.bcmd.2014.05.004","journal-title":"Blood Cells Mol Dis"},{"key":"6977_CR117","doi-asserted-by":"publisher","first-page":"661","DOI":"10.1002\/ajh.24399","volume":"91","author":"GM Pastores","year":"2016","unstructured":"Pastores GM, Shankar SP, Petakov M, Giraldo P, Rosenbaum H, Amato DJ, Szer J, Chertkoff R, Brill-Almon E, Zimran A (2016) Enzyme replacement therapy with taliglucerase alfa: 36-month safety and efficacy results in adult patients with Gaucher disease previously treated with imiglucerase. Am J Hematol 91:661\u2013665. https:\/\/doi.org\/10.1002\/ajh.24399","journal-title":"Am J Hematol"},{"key":"6977_CR118","doi-asserted-by":"publisher","first-page":"1481","DOI":"10.1016\/S0140-6736(00)02161-9","volume":"355","author":"T Cox","year":"2000","unstructured":"Cox T, Lachmann R, Hollak C, Aerts J, van Weely S, Hreb\u00edcek M, Platt F, Butters T, Dwek R, Moyses C, Gow I, Elstein D, Zimran A (2000) Novel oral treatment of Gaucher\u2019s disease with N-butyldeoxynojirimycin (OGT 918) to decrease substrate biosynthesis. Lancet 355:1481\u20131485. https:\/\/doi.org\/10.1016\/S0140-6736(00)02161-9","journal-title":"Lancet"},{"key":"6977_CR119","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1186\/1750-1172-7-102","volume":"7","author":"TM Cox","year":"2012","unstructured":"Cox TM, Amato D, Hollak CE, Luzy C, Silkey M, Giorgino R, Steiner RD, Miglustat Maintenance Study Group (2012) Evaluation of miglustat as maintenance therapy after enzyme therapy in adults with stable type 1 Gaucher disease: a prospective, open-label non-inferiority study. Orphanet J Rare Dis 7:102. https:\/\/doi.org\/10.1186\/1750-1172-7-102","journal-title":"Orphanet J Rare Dis"},{"key":"6977_CR120","doi-asserted-by":"publisher","first-page":"893","DOI":"10.1182\/blood-2010-03-273151","volume":"116","author":"E Lukina","year":"2010","unstructured":"Lukina E, Watman N, Arreguin EA, Banikazemi M, Dragosky M, Iastrebner M, Rosenbaum H, Phillips M, Pastores GM, Rosenthal DI, Kaper M, Singh T, Puga AC, Bonate PL, Peterschmitt MJ (2010) A phase 2 study of eliglustat tartrate (Genz-112638), an oral substrate reduction therapy for Gaucher disease type 1. Blood 116:893\u2013899. https:\/\/doi.org\/10.1182\/blood-2010-03-273151","journal-title":"Blood"},{"key":"6977_CR121","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1001\/jama.2015.459","volume":"313","author":"PK Mistry","year":"2015","unstructured":"Mistry PK, Lukina E, Ben Turkia H, Amato D, Baris H, Dasouki M, Ghosn M, Mehta A, Packman S, Pastores G, Petakov M, Assouline S, Balwani M, Danda S, Hadjiev E, Ortega A, Shankar S, Solano MH, Ross L, Angell J, Peterschmitt MJ (2015) Effect of Oral Eliglustat on Splenomegaly in Patients With Gaucher Disease Type 1: The ENGAGE Randomized Clinical Trial. JAMA 313:695\u2013706. https:\/\/doi.org\/10.1001\/jama.2015.459","journal-title":"JAMA"},{"key":"6977_CR122","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1016\/j.ymgme.2017.12.001","volume":"123","author":"J Charrow","year":"2018","unstructured":"Charrow J, Fraga C, Gu X, Ida H, Longo N, Lukina E, Nonino A, Gaemers SJM, Jouvin MH, Li J, Wu Y, Xue Y, Peterschmitt MJ (2018) Once- versus twice-daily dosing of eliglustat in adults with Gaucher disease type 1: The Phase 3, randomized, double-blind EDGE trial. Mol Genet Metab 123:347\u2013356. https:\/\/doi.org\/10.1016\/j.ymgme.2017.12.001","journal-title":"Mol Genet Metab"},{"key":"6977_CR123","doi-asserted-by":"publisher","first-page":"2355","DOI":"10.1016\/S0140-6736(14)61841-9","volume":"385","author":"TM Cox","year":"2015","unstructured":"Cox TM, Drelichman G, Cravo R, Balwani M, Burrow TA, Martins AM, Lukina E, Rosenbloom B, Ross L, Angell J, Puga AC (2015) Eliglustat compared with imiglucerase in patients with Gaucher\u2019s disease type 1 stabilised on enzyme replacement therapy: a phase 3, randomised, open-label, non-inferiority trial. Lancet 385:2355\u20132362. https:\/\/doi.org\/10.1016\/S0140-6736(14)61841-9","journal-title":"Lancet"},{"key":"6977_CR124","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1007\/s00431-003-1363-z","volume":"163","author":"A Baldellou","year":"2004","unstructured":"Baldellou A, Andria G, Campbell PE, Charrow J, Cohen IJ, Grabowski GA, Harris CM, Kaplan P, McHugh K, Mengel E, Vellodi A (2004) Paediatric non-neuronopathic Gaucher disease: recommendations for treatment and monitoring. Eur J Pediatr 163:67\u201375. https:\/\/doi.org\/10.1007\/s00431-003-1363-z","journal-title":"Eur J Pediatr"},{"key":"6977_CR125","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1111\/j.1399-0004.2007.00769.x","volume":"71","author":"J Charrow","year":"2007","unstructured":"Charrow J, Dulisse B, Grabowski GA, Weinreb NJ (2007) The effect of enzyme replacement therapy on bone crisis and bone pain in patients with type 1 Gaucher disease. Clin Genet 71:205\u2013211. https:\/\/doi.org\/10.1111\/j.1399-0004.2007.00769.x","journal-title":"Clin Genet"},{"key":"6977_CR126","doi-asserted-by":"publisher","first-page":"1045","DOI":"10.1185\/030079906X104623","volume":"22","author":"S vom Dahl","year":"2006","unstructured":"vom Dahl S, Poll L, Di Rocco M, Ciana G, Denes C, Mariani G, Maas M (2006) Evidence-based recommendations for monitoring bone disease and the response to enzyme replacement therapy in Gaucher patients. Curr Med Res Opin 22:1045\u20131064. https:\/\/doi.org\/10.1185\/030079906X104623","journal-title":"Curr Med Res Opin"},{"key":"6977_CR127","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1007\/s00431-012-1771-z","volume":"172","author":"P Kaplan","year":"2013","unstructured":"Kaplan P, Baris H, De Meirleir L, Di Rocco M, El-Beshlawy A, Huemer M, Martins AM, Nascu I, Rohrbach M, Steinbach L, Cohen IJ (2013) Revised recommendations for the management of Gaucher disease in children. Eur J Pediatr 172:447\u2013458. https:\/\/doi.org\/10.1007\/s00431-012-1771-z","journal-title":"Eur J Pediatr"},{"key":"6977_CR128","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1111\/j.1365-2516.2011.02540.x","volume":"18","author":"N Givol","year":"2012","unstructured":"Givol N, Goldstein G, Peleg O, Shenkman B, Zimran A, Elstein D, Kenet G (2012) Thrombocytopenia and bleeding in dental procedures of patients with Gaucher disease. Haemophilia 18:117\u2013121. https:\/\/doi.org\/10.1111\/j.1365-2516.2011.02540.x","journal-title":"Haemophilia"},{"key":"6977_CR129","doi-asserted-by":"publisher","first-page":"1705","DOI":"10.3390\/ijms27041705","volume":"27","author":"F Carubbi","year":"2026","unstructured":"Carubbi F, Linari S, Spada M (2026) Glucosylsphingosine (Lyso-Gb1): An Update on Its Use as a Biomarker in Gaucher Disease. Int J Mol Sci 27:1705. https:\/\/doi.org\/10.3390\/ijms27041705","journal-title":"Int J Mol Sci"},{"key":"6977_CR130","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1007\/s10545-010-9071-0","volume":"33","author":"S Piran","year":"2010","unstructured":"Piran S, Amato D (2010) Gaucher disease: a systematic review and meta-analysis of bone complications and their response to treatment. J Inherit Metab Dis 33:271\u2013279. https:\/\/doi.org\/10.1007\/s10545-010-9071-0","journal-title":"J Inherit Metab Dis"},{"key":"6977_CR131","doi-asserted-by":"publisher","first-page":"996","DOI":"10.1002\/jbmr.3734","volume":"34","author":"D Hughes","year":"2019","unstructured":"Hughes D, Mikosch P, Belmatoug N, Carubbi F, Cox T, Goker-Alpan O, Kindmark A, Mistry P, Poll L, Weinreb N, Deegan P (2019) Gaucher Disease in Bone: From Pathophysiology to Practice. J Bone Min Res 34:996\u20131013. https:\/\/doi.org\/10.1002\/jbmr.3734","journal-title":"J Bone Min Res"},{"key":"6977_CR132","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1016\/j.bcmd.2003.10.007","volume":"32","author":"A Brautbar","year":"2004","unstructured":"Brautbar A, Elstein D, Pines G, Abrahamov A, Zimran A (2004) Effect of enzyme replacement therapy on gammopathies in Gaucher disease. Blood Cells Mol Dis 32:214\u2013217. https:\/\/doi.org\/10.1016\/j.bcmd.2003.10.007","journal-title":"Blood Cells Mol Dis"},{"key":"6977_CR133","doi-asserted-by":"publisher","first-page":"1052","DOI":"10.1002\/ajmg.c.31870","volume":"184","author":"K Abell","year":"2020","unstructured":"Abell K, Chadwell SE, Burrow TA, Becker APP, Bailey L, Steele P, Zhang X, Islas-Ohlmayer M, Bittencourt R, Schwartz IVD, Prada CE (2020) Outcomes of screening for gammopathies in children and adults with Gaucher disease type 1 in a cohort from Brazil and the United States. Am J Med Genet C Semin Med Genet 184:1052\u20131059. https:\/\/doi.org\/10.1002\/ajmg.c.31870","journal-title":"Am J Med Genet C Semin Med Genet"},{"key":"6977_CR134","doi-asserted-by":"publisher","first-page":"1634","DOI":"10.1182\/bloodadvances.2023012304","volume":"8","author":"K Barley","year":"2024","unstructured":"Barley K, Parekh A, Salam S, Mendu DR, Shukla RP, Vatti D, Verina D, Stauffer C, Salib C, El Jamal S, Teruya-Feldstein J, Duffield AS, Leshchenko VV, Jagannath S, Balwani M, Parekh S (2024) Regression of smoldering myeloma with treatment of Gaucher disease. Blood Adv 8:1634\u20131638. https:\/\/doi.org\/10.1182\/bloodadvances.2023012304","journal-title":"Blood Adv"},{"key":"6977_CR135","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1055\/s-0040-1714699","volume":"11","author":"S Yano","year":"2022","unstructured":"Yano S, Moseley K, Mahajan N, Warren M, Vachon L (2022) Large Mesenteric Gaucheroma Responds to Substrate Reduction Therapy: A New Management of Gaucheromas. J Pediatr Genet 11:47\u201350. https:\/\/doi.org\/10.1055\/s-0040-1714699","journal-title":"J Pediatr Genet"},{"key":"6977_CR136","doi-asserted-by":"publisher","first-page":"101106","DOI":"10.1016\/j.ymgmr.2024.101106","volume":"40","author":"S Yano","year":"2024","unstructured":"Yano S, McGowan R, Warren M (2024) Histologic and ultrastructural study of intracranial Gaucheroma causing deafness in a patient with Gaucher disease type 3: Effects of substrate reduction therapy. Mol Genet Metab Rep 40:101106. https:\/\/doi.org\/10.1016\/j.ymgmr.2024.101106","journal-title":"Mol Genet Metab Rep"},{"issue":"20010201","key":"6977_CR137","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1002\/1097-0142","volume":"91","author":"P B\u00f6hm","year":"2001","unstructured":"B\u00f6hm P, Kunz W, Horny HP, Einsele H (2001) Adult Gaucher disease in association with primary malignant bone tumors. Cancer 91(20010201):457\u2013462. https:\/\/doi.org\/10.1002\/1097-0142. )91:3%3C457::AID-CNCR1022%3E3.0.CO;2-J","journal-title":"Cancer"},{"key":"6977_CR138","doi-asserted-by":"publisher","first-page":"e2119","DOI":"10.1212\/WNL.000000000001","volume":"95","author":"T Roshan Lal","year":"2020","unstructured":"Roshan Lal T, Seehra GK, Steward AM, Poffenberger CN, Ryan E, Tayebi N, Lopez G, Sidransky E (2020) The natural history of type 2 Gaucher disease in the 21st century. Neurology 95:e2119\u2013e2130. https:\/\/doi.org\/10.1212\/WNL.000000000001","journal-title":"Neurology"},{"key":"6977_CR139","doi-asserted-by":"publisher","first-page":"2400292","DOI":"10.1002\/adtp.202400292","volume":"8","author":"L Pradhan","year":"2025","unstructured":"Pradhan L, Manna S, Pragya P, Mukherjee S (2025) Recent Therapeutic Advancements for Gaucher Disease. Adv Ther 8:2400292. https:\/\/doi.org\/10.1002\/adtp.202400292","journal-title":"Adv Ther"}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00277-026-06977-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-026-06977-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-026-06977-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,15]],"date-time":"2026-08-15T09:20:27Z","timestamp":1786785627000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00277-026-06977-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,20]]},"references-count":139,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2026,8]]}},"alternative-id":["6977"],"URL":"https:\/\/doi.org\/10.1007\/s00277-026-06977-3","relation":{},"ISSN":["1432-0584"],"issn-type":[{"value":"1432-0584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,20]]},"assertion":[{"value":"27 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no conflicts of interest.","order":2,"name":"Ethics","label":"<b>Conflict of interests<\/b>","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"333"}}